[1] |
Ostron QT, Gittlem ANH, Fulop J, et al. Cbtrus statistical report:primay brain and central nervous system tumors diagnosed in the United States in 2008-2012[J]. Neuro Oncol, 2015,17(4):1-62.
DOI
URL
|
[2] |
Nabors LB, Portnow J, Ammirati MJ. NCCN guidelines insights:central nervous,system cancers,Version1. 2017[J]. J Natl Compr Canc Netw, 2017,15(11):1331-1345.
DOI
URL
PMID
|
[3] |
Kirson ED, Gurvich Z, Schneiderman R, et al. Disruption of can-cer cell replication by alter-nating electric fields[J]. Cancer Res, 2004,64(9):3288-3295.
DOI
URL
PMID
|
[4] |
Ornelas AS, Porter AB, Sharma A, et al. What is the role of tumor-treating fields in newly diagnosed glioblastoma?[J]. Neurologist, 2019,24(2):71-73.
DOI
URL
PMID
|
[5] |
Magouliotis DE, Asprodini EK, Svokos KA, et,al. Tumor-treating fields as a fourth treating modality for glioblastoma:a meta-analysis[J]. Acta Neurochir(Wien), 2018,160(6):1167-1174.
DOI
URL
|
[6] |
Wenger C, Miranda PC, Salvador R, et al. A review on tumor-treating fields:clinical implications inferred from computational modeling[J]. IEEE Rev Biomed Eng, 2018,11:195-207.
DOI
URL
PMID
|
[7] |
Lacouture ME, Davis ME, Elzinga G, et al. Characterization and management of dermatologic events with the NovoTTF-100A system,a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma[J]. Semin Oncol, 2014,41(4):1-14.
DOI
URL
|
[8] |
Lukas RV, Ratermann KL, Wong ET, et al. Skin toxicities associated with tumor treating fields:case based review[J]. J Neurooncol, 2017,135(3):593-599.
DOI
URL
PMID
|
[9] |
Janlyn M, Marry EB, Loretta B. Optune? Practical nursing applications[J]. Clin J Oncol Nurs. 2016,20(5):14-19.
|